Compare CHRD & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRD | ALKS |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | Ireland |
| Employees | 676 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.7B |
| IPO Year | N/A | 2012 |
| Metric | CHRD | ALKS |
|---|---|---|
| Price | $132.20 | $51.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $149.17 | $43.43 |
| AVG Volume (30 Days) | 776.5K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $12.56 | $24.26 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | $34.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.25 | $25.17 |
| 52 Week High | $151.95 | $55.67 |
| Indicator | CHRD | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 51.02 |
| Support Level | $86.73 | $50.49 |
| Resistance Level | $141.72 | $55.67 |
| Average True Range (ATR) | 3.49 | 1.68 |
| MACD | 1.69 | -0.55 |
| Stochastic Oscillator | 57.92 | 30.88 |
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.